BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stachler MD, Camarda ND, Deitrick C, Kim A, Agoston AT, Odze RD, Hornick JL, Nag A, Thorner AR, Ducar M, Noffsinger A, Lash RH, Redston M, Carter SL, Davison JM, Bass AJ. Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma. Gastroenterology 2018;155:156-67. [PMID: 29608884 DOI: 10.1053/j.gastro.2018.03.047] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 13.5] [Reference Citation Analysis]
Number Citing Articles
1 Konda VJA, Souza RF. Barrett’s Esophagus and Esophageal Carcinoma: Can Biomarkers Guide Clinical Practice? Curr Gastroenterol Rep 2019;21. [DOI: 10.1007/s11894-019-0685-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
2 Toon C, Allanson B, Leslie C, Acott N, Mirzai B, Raftopoulos S, Kumarasinghe MP. Patterns of p53 immunoreactivity in non-neoplastic and neoplastic Barrett's mucosa of the oesophagus: in-depth evaluation in endoscopic mucosal resections. Pathology 2019;51:253-60. [DOI: 10.1016/j.pathol.2018.12.415] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
3 Talukdar FR, di Pietro M, Secrier M, Moehler M, Goepfert K, Lima SSC, Pinto LFR, Hendricks D, Parker MI, Herceg Z. Molecular landscape of esophageal cancer: implications for early detection and personalized therapy. Ann N Y Acad Sci 2018;1434:342-59. [PMID: 29917250 DOI: 10.1111/nyas.13876] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
4 Lam KK, Thean LF, Cheah PY. Advances in colorectal cancer genomics and transcriptomics drive early detection and prevention. Int J Biochem Cell Biol 2021;137:106032. [PMID: 34182137 DOI: 10.1016/j.biocel.2021.106032] [Reference Citation Analysis]
5 Ray P, Nancarrow DJ, Ferrer-Torres D, Wang Z, San Martinho M, Hinton T, Wu JH, Wu A, Turgeon DK, Hammer MA, Dame MK, Lawrence TS, O'Brien PJ, Spence JR, Beer DG, Ray D. UBCH5 Family Members Differentially Impact Stabilization of Mutant p53 via RNF128 Iso1 During Barrett's Progression to Esophageal Adenocarcinoma. Cell Mol Gastroenterol Hepatol 2021;13:129-49. [PMID: 34416429 DOI: 10.1016/j.jcmgh.2021.08.003] [Reference Citation Analysis]
6 Yin F, Hernandez Gonzalo D, Lai J, Liu X. Histopathology of Barrett’s Esophagus and Early-Stage Esophageal Adenocarcinoma: An Updated Review. GastrointestDisord 2018;1:147-63. [DOI: 10.3390/gidisord1010011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Zhao Y, Ma T, Zhang Z, Chen X, Zhou C, Zhang L, Zou D. Resolvin D1 attenuates acid-induced DNA damage in esophageal epithelial cells and rat models of acid reflux. Eur J Pharmacol 2021;912:174571. [PMID: 34656605 DOI: 10.1016/j.ejphar.2021.174571] [Reference Citation Analysis]
8 Douville C, Moinova HR, Thota PN, Shaheen NJ, Iyer PG, Canto MI, Wang JS, Dumot JA, Faulx A, Kinzler KW, Papadopoulos N, Vogelstein B, Markowitz SD, Bettegowda C, Willis JE, Chak A. Massively Parallel Sequencing of Esophageal Brushings Enables an Aneuploidy-Based Classification of Patients With Barrett's Esophagus. Gastroenterology 2021;160:2043-2054.e2. [PMID: 33493502 DOI: 10.1053/j.gastro.2021.01.209] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Huo X, Dunbar KB, Zhang X, Zhang Q, Spechler SJ, Souza RF. In Barrett's epithelial cells, weakly acidic bile salt solutions cause oxidative DNA damage with response and repair mediated by p38. Am J Physiol Gastrointest Liver Physiol 2020;318:G464-78. [PMID: 31984785 DOI: 10.1152/ajpgi.00329.2019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kakiuchi N, Ogawa S. Clonal expansion in non-cancer tissues. Nat Rev Cancer 2021;21:239-56. [DOI: 10.1038/s41568-021-00335-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 13.0] [Reference Citation Analysis]
11 Killcoyne S, Yusuf A, Fitzgerald RC. Genomic instability signals offer diagnostic possibility in early cancer detection. Trends Genet 2021:S0168-9525(21)00165-7. [PMID: 34218956 DOI: 10.1016/j.tig.2021.06.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Jin RU, Mills JC. The cyclical hit model: how paligenosis might establish the mutational landscape in Barrett's esophagus and esophageal adenocarcinoma. Current Opinion in Gastroenterology 2019;35:363-70. [DOI: 10.1097/mog.0000000000000540] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
13 Porter RJ, Murray GI, Brice DP, Petty RD, McLean MH. Novel biomarkers for risk stratification of Barrett's oesophagus associated neoplastic progression-epithelial HMGB1 expression and stromal lymphocytic phenotype. Br J Cancer 2020;122:545-54. [PMID: 31831860 DOI: 10.1038/s41416-019-0685-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
14 Hoppe S, Jonas C, Wenzel MC, Velazquez Camacho O, Arolt C, Zhao Y, Büttner R, Quaas A, Plum PS, Hillmer AM. Genomic and Transcriptomic Characteristics of Esophageal Adenocarcinoma. Cancers (Basel) 2021;13:4300. [PMID: 34503107 DOI: 10.3390/cancers13174300] [Reference Citation Analysis]
15 Redston M, Noffsinger A, Kim A, Akarca FG, Rara M, Stapleton D, Nowden L, Lash R, Bass AJ, Stachler MD. Abnormal TP53 predicts risk of progression in patients with Barrett's esophagus regardless of a diagnosis of dysplasia. Gastroenterology 2021:S0016-5085(21)03710-0. [PMID: 34757142 DOI: 10.1053/j.gastro.2021.10.038] [Reference Citation Analysis]
16 Hoefnagel SJM, Mostafavi N, Timmer MR, Lau CT, Meijer SL, Wang KK, Krishnadath KK. A genomic biomarker-based model for cancer risk stratification of non-dysplastic Barrett's esophagus patients after extended follow up; results from Dutch surveillance cohorts. PLoS One 2020;15:e0231419. [PMID: 32282835 DOI: 10.1371/journal.pone.0231419] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Cook MB, Thrift AP. Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma: Implications for Screening and Surveillance. Gastrointest Endosc Clin N Am 2021;31:1-26. [PMID: 33213789 DOI: 10.1016/j.giec.2020.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Caspa Gokulan R, Garcia-Buitrago MT, Zaika AI. From genetics to signaling pathways: molecular pathogenesis of esophageal adenocarcinoma. Biochim Biophys Acta Rev Cancer 2019;1872:37-48. [PMID: 31152823 DOI: 10.1016/j.bbcan.2019.05.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
19 Dam AN, Klapman J. A narrative review of Barrett's esophagus in 2020, molecular and clinical update.Ann Transl Med. 2020;8:1107. [PMID: 33145326 DOI: 10.21037/atm-20-4406] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Sepulveda JL, Komissarova EV, Kongkarnka S, Friedman RA, Davison JM, Levy B, Bryk D, Jobanputra V, Del Portillo A, Falk GW, Sonett JR, Lightdale CJ, Abrams JA, Wang TC, Sepulveda AR. High-resolution genomic alterations in Barrett's metaplasia of patients who progress to esophageal dysplasia and adenocarcinoma. Int J Cancer 2019;145:2754-66. [PMID: 31001805 DOI: 10.1002/ijc.32351] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
21 Schmidt M, Hackett RJ, Baker AM, McDonald SAC, Quante M, Graham TA. Evolutionary dynamics in Barrett oesophagus: implications for surveillance, risk stratification and therapy. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34728819 DOI: 10.1038/s41575-021-00531-4] [Reference Citation Analysis]
22 Sethi NS, Kikuchi O, Duronio GN, Stachler MD, McFarland JM, Ferrer-Luna R, Zhang Y, Bao C, Bronson R, Patil D, Sanchez-Vega F, Liu JB, Sicinska E, Lazaro JB, Ligon KL, Beroukhim R, Bass AJ. Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model. Nat Genet 2020;52:219-30. [PMID: 32025000 DOI: 10.1038/s41588-019-0574-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
23 Stachler MD, Bass AJ. Can Genomic Sequencing Identify High-Risk Barrett's Esophagus Earlier Than Pathologists? Cancer Cell 2020;38:626-8. [PMID: 33171128 DOI: 10.1016/j.ccell.2020.10.020] [Reference Citation Analysis]
24 Snyder P, Dunbar K, Cipher DJ, Souza RF, Spechler SJ, Konda VJA. Aberrant p53 Immunostaining in Barrett's Esophagus Predicts Neoplastic Progression: Systematic Review and Meta-Analyses. Dig Dis Sci 2019;64:1089-97. [PMID: 30911864 DOI: 10.1007/s10620-019-05586-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
25 Wartak A, Kelada AK, Leon Alarcon PA, Bablouzian AL, Ahsen OO, Gregg AL, Wei Y, Bollavaram K, Sheil CJ, Farewell E, VanTol S, Smith R, Grahmann P, Baillargeon AR, Gardecki JA, Tearney GJ. Dual-modality optical coherence tomography and fluorescence tethered capsule endomicroscopy. Biomed Opt Express 2021;12:4308-23. [PMID: 34457416 DOI: 10.1364/BOE.422453] [Reference Citation Analysis]
26 Davison JM, Shah MB, Deitrick C, Chennat J, Fasanella KE, Mcgrath K. Low-grade dysplasia diagnosis ratio and progression metrics identify variable Barrett’s esophagus risk stratification proficiency in independent pathology practices. Gastrointestinal Endoscopy 2018;88:807-815.e2. [DOI: 10.1016/j.gie.2018.06.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
27 Weh KM, Zhang Y, Howard CL, Howell AB, Clarke JL, Kresty LA. Cranberry Polyphenols in Esophageal Cancer Inhibition: New Insights. Nutrients 2022;14:969. [DOI: 10.3390/nu14050969] [Reference Citation Analysis]
28 Frei NF, Bergman JJGHM, Pouw RE. Screening for Barrett's esophagus: Ready for prime time or still hard to swallow? Gastrointest Endosc 2021;94:506-8. [PMID: 34275609 DOI: 10.1016/j.gie.2021.06.004] [Reference Citation Analysis]
29 Frei NF, Stachler MD, Bergman JJGHM. Risk stratification in Barrett's esophagus patients with diagnoses of indefinite for dysplasia: the definite silver bullet has not (yet) been found. Gastrointest Endosc 2020;91:11-3. [PMID: 31865984 DOI: 10.1016/j.gie.2019.09.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
30 Sen M, Hahn F, Black TA, DeMarshall M, Porter W, Snowden E, Yee SS, Tong F, Ferguson M, Fleshman EN, Nakagawa H, Falk GW, Ginsberg GG, Kochman ML, Blaesius R, Rustgi AK, Carpenter EL. Flow based single cell analysis of the immune landscape distinguishes Barrett's esophagus from adjacent normal tissue. Oncotarget 2019;10:3592-604. [PMID: 31217895 DOI: 10.18632/oncotarget.26911] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
31 Garman KS. Drivers of Esophageal Adenocarcinoma and Opportunities for Cancer Interception. Cell Mol Gastroenterol Hepatol 2021;12:787-8. [PMID: 34029533 DOI: 10.1016/j.jcmgh.2021.04.018] [Reference Citation Analysis]
32 Gabre J, Chak A, Rustgi A. Familial Barrett’s Esophagus and Esophageal Adenocarcinoma. Curr Treat Options Gastro 2020;18:616-22. [DOI: 10.1007/s11938-020-00313-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Tokunaga M, Okimoto K, Akizue N, Ishikawa K, Hirotsu Y, Amemiya K, Ota M, Matsusaka K, Nishimura M, Matsushita K, Ishikawa T, Nagashima A, Shiratori W, Kaneko T, Oura H, Kanayama K, Ohta Y, Taida T, Saito K, Matsumura T, Chiba T, Mochizuki H, Arai M, Kato J, Ikeda JI, Omata M, Kato N. Genetic profiles of Barrett's esophagus and esophageal adenocarcinoma in Japanese patients. Sci Rep 2021;11:17671. [PMID: 34480065 DOI: 10.1038/s41598-021-97249-9] [Reference Citation Analysis]
34 Rogerson C, Ogden S, Britton E, Ang Y, Sharrocks AD; OCCAMS Consortium. Repurposing of KLF5 activates a cell cycle signature during the progression from a precursor state to oesophageal adenocarcinoma. Elife 2020;9:e57189. [PMID: 32880368 DOI: 10.7554/eLife.57189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
35 Lowenthal BM, Nason KS, Pennathur A, Luketich JD, Pai RK, Davison JM, Ma C. Loss of ARID1A expression is associated with DNA mismatch repair protein deficiency and favorable prognosis in advanced stage surgically resected esophageal adenocarcinoma. Hum Pathol 2019;94:1-10. [PMID: 31655170 DOI: 10.1016/j.humpath.2019.09.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
36 Martinho MS, Nancarrow DJ, Lawrence TS, Beer DG, Ray D. Chaperones and Ubiquitin Ligases Balance Mutant p53 Protein Stability in Esophageal and Other Digestive Cancers. Cell Mol Gastroenterol Hepatol 2021;11:449-64. [PMID: 33130332 DOI: 10.1016/j.jcmgh.2020.10.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Tokuyama M, Geisler D, Deitrick C, Fasanella KE, Chennat JS, McGrath KM, Pai RK, Davison JM. Use of p53 immunohistochemistry in conjunction with routine histology improves risk stratification of patients with Barrett's oesophagus during routine clinical care. Histopathology 2020;77:481-91. [PMID: 32431062 DOI: 10.1111/his.14143] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
38 Souza RF, Spechler SJ. Advances in Biomarkers for Risk Stratification in Barrett's Esophagus. Gastrointest Endosc Clin N Am 2021;31:105-15. [PMID: 33213790 DOI: 10.1016/j.giec.2020.08.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Guccione C, Yadlapati R, Shah S, Knight R, Curtius K. Challenges in Determining the Role of Microbiome Evolution in Barrett's Esophagus and Progression to Esophageal Adenocarcinoma. Microorganisms 2021;9:2003. [PMID: 34683324 DOI: 10.3390/microorganisms9102003] [Reference Citation Analysis]
40 Zhang X, Wang Y, Meng L. Comparative genomic analysis of esophageal squamous cell carcinoma and adenocarcinoma: New opportunities towards molecularly targeted therapy. Acta Pharmaceutica Sinica B 2022;12:1054-67. [DOI: 10.1016/j.apsb.2021.09.028] [Reference Citation Analysis]
41 Sahgal P, Huffman BM, Patil DT, Chatila WK, Yaeger R, Cleary JM, Sethi NS. Early TP53 Alterations Shape Gastric and Esophageal Cancer Development. Cancers (Basel) 2021;13:5915. [PMID: 34885025 DOI: 10.3390/cancers13235915] [Reference Citation Analysis]
42 Davison JM, Goldblum J, Grewal US, McGrath K, Fasanella K, Deitrick C, DeWard AD, Bossart EA, Hayward SL, Zhang Y, Critchley-Thorne RJ, Thota PN. Independent Blinded Validation of a Tissue Systems Pathology Test to Predict Progression in Patients With Barrett's Esophagus. Am J Gastroenterol 2020;115:843-52. [PMID: 32079863 DOI: 10.14309/ajg.0000000000000556] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
43 Maslyonkina KS, Konyukova AK, Alexeeva DY, Sinelnikov MY, Mikhaleva LM. Barrett's esophagus: The pathomorphological and molecular genetic keystones of neoplastic progression. Cancer Med 2021. [PMID: 34870375 DOI: 10.1002/cam4.4447] [Reference Citation Analysis]
44 Quante M, Wang TC, Bass AJ. Adenocarcinoma of the oesophagus: is it gastric cancer? Gut 2022:gutjnl-2022-327096. [PMID: 35365571 DOI: 10.1136/gutjnl-2022-327096] [Reference Citation Analysis]
45 Stachler MD, Jin RU. Molecular Pathology of Gastroesophageal Cancer. Surg Pathol Clin 2021;14:443-53. [PMID: 34373095 DOI: 10.1016/j.path.2021.05.008] [Reference Citation Analysis]
46 Borden ES, Kang P, Natri HM, Phung TN, Wilson MA, Buetow KH, Hastings KT. Neoantigen Fitness Model Predicts Lower Immune Recognition of Cutaneous Squamous Cell Carcinomas Than Actinic Keratoses. Front Immunol 2019;10:2799. [PMID: 31849976 DOI: 10.3389/fimmu.2019.02799] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
47 Bornschein J, Quante M, Jansen M. The complexity of cancer origins at the gastro-oesophageal junction. Best Pract Res Clin Gastroenterol 2021;50-51:101729. [PMID: 33975686 DOI: 10.1016/j.bpg.2021.101729] [Reference Citation Analysis]
48 García-Foncillas J, Argente J, Bujanda L, Cardona V, Casanova B, Fernández-Montes A, Horcajadas JA, Iñiguez A, Ortiz A, Pablos JL, Pérez Gómez MV. Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview. Mol Diagn Ther 2021;25:563-76. [PMID: 34331269 DOI: 10.1007/s40291-021-00544-4] [Reference Citation Analysis]
49 Hadjinicolaou AV, van Munster SN, Achilleos A, Santiago Garcia J, Killcoyne S, Ragunath K, Bergman JJGHM, Fitzgerald RC, di Pietro M. Aneuploidy in targeted endoscopic biopsies outperforms other tissue biomarkers in the prediction of histologic progression of Barrett's oesophagus: A multi-centre prospective cohort study. EBioMedicine 2020;56:102765. [PMID: 32460165 DOI: 10.1016/j.ebiom.2020.102765] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
50 Borgmann M, Quante M. Impact of the Tumor Microenvironment for Esophageal Tumor Development—An Opportunity for Prevention? Cancers 2022;14:2246. [DOI: 10.3390/cancers14092246] [Reference Citation Analysis]
51 Killcoyne S, Fitzgerald RC. Evolution and progression of Barrett's oesophagus to oesophageal cancer. Nat Rev Cancer 2021;21:731-41. [PMID: 34545238 DOI: 10.1038/s41568-021-00400-x] [Reference Citation Analysis]
52 Frei NF, Khoshiwal AM, Konte K, Bossart EA, Stebbins K, Zhang Y, Pouw RE, Ten Kate FJW, Seldenrijk KA, Meijer SL, Critchley-Thorne RJ, Bergman JJGHM. Tissue Systems Pathology Test Objectively Risk Stratifies Barrett's Esophagus Patients With Low-Grade Dysplasia. Am J Gastroenterol 2021;116:675-82. [PMID: 33982936 DOI: 10.14309/ajg.0000000000001037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
53 Busslinger GA, de Barbanson B, Oka R, Weusten BLA, de Maat M, van Hillegersberg R, Brosens LAA, van Boxtel R, van Oudenaarden A, Clevers H. Molecular characterization of Barrett's esophagus at single-cell resolution. Proc Natl Acad Sci U S A 2021;118:e2113061118. [PMID: 34795059 DOI: 10.1073/pnas.2113061118] [Reference Citation Analysis]
54 Karamchandani DM, Zhang Q, Liao XY, Xu JH, Liu XL. Inflammatory bowel disease- and Barrett's esophagus-associated neoplasia: the old, the new, and the persistent struggles. Gastroenterol Rep (Oxf) 2019;7:379-95. [PMID: 31857901 DOI: 10.1093/gastro/goz032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]